Roche to pay $184M for cancer-detection firm; MedImmune begins flu vax shipments;

@FiercePharma: Roche to post 'massive' margin boost, paper says. Item | Follow @FiercePharma

> Roche has agreed to buy Germany's mtm laboratories for an initial €130 million ($184 million), deepening the Swiss drugmaker's expertise in early detection and diagnosis of cervical cancer. News

> MedImmune, a unit of AstraZeneca, said it expects to ship between 15 million and 16 million doses of its three-strain influenza vaccine for the upcoming flu season. Item

> Two antidepressants commonly given to Alzheimer's disease patients--Zoloft and Remeron--appear to be ineffective, and they may trigger side effects such as nausea and drowsiness, a Lancet study found. Story

> Sihuan Pharmaceutical said it would sell a 50% stake in a wholly owned drug products distributor to Shandong Buchang Pharmaceutical for 637.5 million yuan ($98.55 million). Article

> GlaxoSmithKline purchased 1.2 million of its Ordinary shares of 25 pence each and said it intends to hold these shares in Treasury. Piece

> Alkermes forecast fiscal 2012 revenue will grow as much as 6.7% to $480 million after it completes the purchase of Elan's drug technology unit this year. Report

> Lonza has won a contract to manufacture Immune Pharmaceuticals' antibody-based drug for inflammatory disorders, bertilimumab, at its manufacturing facility in the U.K. News

> The international body that oversees drug programs in sports is negotiating with "many" pharmaceutical companies to share information in an effort to prevent cheating, the group's president said. Story

Biotech News

@FierceBiotech: Nabi shares in meltdown after NicVAX flunks Ph3. Story | Follow @FierceBiotech

@JohnCFierce: Look for Alkermes to talk a lot about sustained growth with EDT acquisition. Here's the PR: Release | Follow @JohnCFierce

> Merck confronts tough odds pioneering experimental sleep drug. Report

> Alkermes CEO Pops is taking a run at the big league. Item 

Biotech Research News

> Group launches program to develop drugs for pediatric HIV. Article

> Addiction recognized as medical condition, not lack of willpower. News 

> Lack of funding shuts down Maine biotech research. Piece

> Nanosensors on cells show how they communicate in real time. Report 

> Mice receive artificial human liver for drug testing. Item 

Manufacturing News

> One man's foreign-source warning is another's generics bash. News

> MIT works toward bioprocess predictability, drug quality. Report

> Intel eyes pharma road to 'next billion users.' Story 

> WHO touts flu, pandemic vax readiness. Item

> Rx-360 shores up raw material security. Story

And Finally... Antidepressants appear to decrease the amount of a substance thought to be a contributor to Alzheimer's disease, according to new animal research. Report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.